SRC and cancer: The suppressive effect of dasatinib on TGF-β signalling is likely mediated by inhibition of the ALK5 kinase activity and may be exploited therapeutically in more advanced PDAC (when TGF-β1 expression and SRC activity are high) to synergistically reduce invasion, metastasis and eventually cancer stem cell formation.